Cat. No.: HY-14463

Onalespib

(Synonyms: AT13387)

11 Cited Publications

Customer Review

Based on 11 publication(s) in Google Scholar

Onalespib (AT13387) is a potent and cross the blood-brain barrier heat-shock-protein-90 (Hsp90) inhibitor. Onalespib inhibits the proliferation, survival and migration. Onalespib decreases the expression of EGFR, p-EGFR, AKT, P-AKT, ERK1/2, P-ERK1/2, S6, P-S6 protein. Onalespib shows antitumor activity. Onalespib has the potential for the research of non-small cell lung cancer (NSCLC).

For research use only. We do not sell to patients.

Purity: 99.92%
CAS No.: 912999-49-6
Formula: C₂₄H₃₁N₃O₃
Molecular Weight:409.52

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Onalespib Chemical Structure

CAS No.: 912999-49-6

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (11)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

HSP90

0.71 nM (Kd)

All HSP Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	0.05 μM Compound: 8; AT13387	Antiproliferative activity against human A549 assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 27933959]
A549	IC₅₀	0.44 μM Compound: AT13387	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 30784881]
BT-474	IC₅₀	0.032 μM Compound: 8; AT13387	Antiproliferative activity against human BT-474 assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human BT-474 assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 27933959]
GIST430	IC₅₀	34 nM Compound: 8; AT-13387	Cytotoxicity against imatinib-resistant human GIST430 cells assessed as decrease in cell viability after 7 days by alamar blue assay Cytotoxicity against imatinib-resistant human GIST430 cells assessed as decrease in cell viability after 7 days by alamar blue assay	[PMID: 26844689]
GIST48	IC₅₀	55 nM Compound: 8; AT-13387	Cytotoxicity against imatinib-resistant human GIST48 cells assessed as decrease in cell viability after 7 days by alamar blue assay Cytotoxicity against imatinib-resistant human GIST48 cells assessed as decrease in cell viability after 7 days by alamar blue assay	[PMID: 26844689]
HCT-116	IC₅₀	0.07 μM Compound: 8; AT13387	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 27933959]
HCT-116	IC₅₀	0.08 μM Compound: AT-13387	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 24763261]
HCT-116	IC₅₀	48 nM Compound: 35	Cytotoxicity against human HCT116 cells by Alamar blue assay Cytotoxicity against human HCT116 cells by Alamar blue assay	[PMID: 20662534]
HCT-116	IC₅₀	78.49 nM Compound: AT13387	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay	[PMID: 39145509]
HepG2	IC₅₀	0.018 μM Compound: 8; AT13387	Antiproliferative activity against human HepG2 assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HepG2 assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 27933959]
K562	IC₅₀	0.038 μM Compound: 8; AT13387	Antiproliferative activity against human K562 assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human K562 assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 27933959]
L02	IC₅₀	11.64 μM Compound: 8; AT13387	Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 27933959]
MCF7	IC₅₀	0.02 μM Compound: 8; AT13387	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 27933959]
MCF7	IC₅₀	0.032 μM Compound: AT13387	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay	[PMID: 29028527]
MCF7	IC₅₀	0.28 μM Compound: AT-13387	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 24763261]
MCF7	IC₅₀	0.29 μM Compound: AT13387	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 30784881]
MCF7	IC₅₀	0.84 μM Compound: AT13387	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 37619298]
MDA-MB-231	IC₅₀	0.038 μM Compound: 8; AT13387	Antiproliferative activity against human MDA-MB-231 assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 27933959]
MDA-MB-231	IC₅₀	2.6 μM Compound: AT13387	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 37619298]
MDA-MB-468	IC₅₀	0.066 μM Compound: 8; AT13387	Antiproliferative activity against human MDA-MB-468 assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-468 assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 27933959]
MDA-MB-468	IC₅₀	3.31 μM Compound: AT13387	Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 37619298]
MKN-28	IC₅₀	0.129 μM Compound: 8; AT13387	Antiproliferative activity against human MKN-28 assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human MKN-28 assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 27933959]
MV4-11	IC₅₀	0.011 μM Compound: 8; AT13387	Antiproliferative activity against human MV4-11 assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human MV4-11 assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 27933959]
MX1	IC₅₀	0.5 μM Compound: AT13387	Antiproliferative activity against human MX1 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human MX1 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 37619298]
NCI-H1299	IC₅₀	0.37 μM Compound: AT13387	Antiproliferative activity against human NCI-H1299 cells after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1299 cells after 72 hrs by MTT assay	[PMID: 30784881]
NCI-H3122	IC₅₀	52 nM Compound: AT13387	Antiproliferative activity against human NCI-H3122 cells after 72 hrs by SRB assay Antiproliferative activity against human NCI-H3122 cells after 72 hrs by SRB assay	[PMID: 29698859]
SK-BR-3	IC₅₀	0.045 μM Compound: AT13387	Antiproliferative activity against human SKBR3 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human SKBR3 cells incubated for 72 hrs by MTT assay	[PMID: 29028527]
SK-BR-3	IC₅₀	0.071 μM Compound: 8; AT13387	Antiproliferative activity against human SK-BR-3 assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human SK-BR-3 assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 27933959]
SK-BR-3	IC₅₀	0.14 μM Compound: AT-13387	Antiproliferative activity against human SKBR3 cells after 48 hrs by MTT assay Antiproliferative activity against human SKBR3 cells after 48 hrs by MTT assay	[PMID: 24763261]
SW-620	IC₅₀	122.3 nM Compound: AT13387	Antiproliferative activity against human SW620 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay Antiproliferative activity against human SW620 cells assessed as inhibition of cell proliferation incubated for 72 hrs by CCK8 assay	[PMID: 39145509]
T47D	IC₅₀	0.024 μM Compound: 8; AT13387	Antiproliferative activity against human T47D assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human T47D assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 27933959]
U2OS	IC₅₀	0.067 μM Compound: 8; AT13387	Antiproliferative activity against human U2OS assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human U2OS assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 27933959]

In Vitro

Onalespib (0-0.4 µM; 72 h, 48 h) inhibits the proliferation, survival and migration of glioma cells^[2].
Onalespib (0-0.4 µM; 48 h) decreases the expression of EGFR, p-EGFR, AKT, P-AKT, ERK1/2, P-ERK1/2, S6, P-S6 protein in a dose-dependent manner^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Onalespib (30 mg/kg; i.v.; once) crosses the blood-brain barrier (BBB) and causes sustained inhibition of HSP90 in 6-week-old ICR mice^[2].
Onalespib (0.5 µM; from 5 to 10 days post-transplant) and TMZ (10 µM) reduce tumor growth and extend survival in zebrafish embryos^[2].
Onalespib (5, 10 mg/kg for HCT116 xenografts, 20 mg/kg for A431 xenografts; i.p.; daily for 3 days) shows anti-tumor activity in HCT116 and A431 xenografts^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 912999-49-6
Appearance Solid
Molecular Weight 409.52
Formula C₂₄H₃₁N₃O₃
Color Off-white to gray
SMILES

OC1=CC(O)=C(C(C)C)C=C1C(N2CC(C=CC(CN3CCN(C)CC3)=C4)=C4C2)=O
Synonyms

AT13387
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (11)

All Histological Imaging/StainingBio/Physico-chemical AssayApoptosis AnalysisCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Theranostics

Inhibition of HSP90β Improves Lipid Disorders by Promoting Mature SREBPs Degradation via the Ubiquitin-proteasome System. [Abstract]

2019 Aug 12;9(20):5769-5783. PMID: 31534518
Nano Res

07 May 2022.
Immunology

Inhibition of the NLRP3 inflammasome by HSP90 inhibitors. [Abstract]

2021 Jan;162(1):84-91. PMID: 32954500
Sci Rep

Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics. [Abstract]

2017 Mar 15;7(1):201. PMID: 28298630

Onalespib purchased from MedChemExpress. Usage Cited in: Sci Rep. 2017 Mar 15;7(1):201. [Abstract]

5637 and SV-HUC cells (1 × 10⁴ per well) were evenly distributed in 96-well plates overnight. Cells were incubated with AUY922 (10 nM), ganetespib (10 nM), SNX2112 (100 nM), or AT13387 (Onalespib) (100 nM) for 48 h. For the caspase 3/7 assay, the HSP90 inhibitor-treated 5637 or SV-HUC cells are stained with Nexcelom ViaStain Caspase 3/7 reagent and Hoechst 33342. Caspase 3/7 positive cells are identified using the Celigo imaging cytometer, and the percentage of apoptotic caspase 3/7 positive cells is calculated with the Celigo software.

Onalespib purchased from MedChemExpress. Usage Cited in: Sci Rep. 2017 Mar 15;7(1):201. [Abstract]

Heat shock protein 90 (HSP90) inhibitors suppress cell growth and proliferation in human bladder carcinoma cells. 5637 cells were evenly distributed in 96-well plates (5 × 10³ cells/well) and treated for 72 h with AUY922, ganetespib (STA9090), SNX2112, AT13387 (Onalespib), or CUDC395 at the indicated concentrations. The ability of HSP90 inhibitors to inhibit cell growth and proliferation was determined by the MTS assay.
J Appl Toxicol

Mechanism of graphene-induced cytotoxicity: Role of endonucleases. [Abstract]

2017 Nov;37(11):1325-1332. PMID: 28543094

Onalespib purchased from MedChemExpress. Usage Cited in: J Appl Toxicol. 2017 Nov;37(11):1325-1332. [Abstract]

Alleviation of graphene toxicity by using chemical inhibitors (Onalespib (AT13387 et al; 20 nM pretreatment 2 h)) after 48 h exposure of NRK-52E cells with graphene (50 μg/ml). Quantification of TUNEL-positive cells in NRK-52E cells treated with graphene in the presence of chemical inhibitors for HO-1, HSP90, caspase 3, DNase I and EndoG (p < 0.01 for all bars vs. Gn).
Prostate

Diptoindonesin G antagonizes AR signaling and enhances the efficacy of antiandrogen therapy in prostate cancer. [Abstract]

2022 Jun;82(8):917-932. PMID: 35322879
J Labelled Comp Radiopharm

Radiosynthesis and Evaluation of [18F]FEHSP990 as Novel PET Tracer for Hsp90 PET Imaging. [Abstract]

2025 Apr;68(4):e4144. PMID: 40219580

Onalespib purchased from MedChemExpress. Usage Cited in: J Labelled Comp Radiopharm. 2025 Apr;68(4):e4144. [Abstract]

In vitro autoradiography study. Slices were incubated with [¹⁸F]FEHSP990 (11 kBq/mL). Binding specificity was assessed by preincubation with authentic reference compound (FEHSP990), homologous (HSP990) and heterologous (Onalespib, PU‐H71) inhibitors (10 μM; 10 min) at RT. Rat brain slices (n = 3 per preincubation condition) and U87 tumour slices (n = 3 per preincubation condition).

Onalespib purchased from MedChemExpress. Usage Cited in: J Labelled Comp Radiopharm. 2025 Apr;68(4):e4144. [Abstract]

In vitro cell binding study. U87 cells were incubated with [¹⁸F]FEHSP990 (84 kBq/mL). Binding specificity was assessed by preincubation with homologous (HSP990) and heterologous (Onalespib, PU‐H71) inhibitors (100 μM; 60 min) at 37°C (n = 3 per preincubation condition).
Research Square Preprint

2024 Oct 10.
Research Square Print

December 12th, 2022.
Oncotarget

MEK is a promising target in the basal subtype of bladder cancer. [Abstract]

2020 Nov 3;11(44):3921-3932. PMID: 33216841
Methods Mol Biol

Methods for High-throughput Drug Combination Screening and Synergy Scoring. [Abstract]

2018:1711:351-398. PMID: 29344898

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (122.09 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.4419 mL

12.2094 mL

24.4188 mL

5 mM

0.4884 mL

2.4419 mL

4.8838 mL

10 mM

0.2442 mL

1.2209 mL

2.4419 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.10 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.10 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.10 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 16.67 mg/mL (40.71 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Animal Administration^[1]

HCT116 cells are injected SC into the right hind flank of male nude BALB/c mice. Tumours are apparent 7 to 10 days later. Mice are arranged into matched groups of 12 according to tumour volume giving a group mean of approximately 100 mm^[3] at initiation of dosing. Tumour volumes are measured every 2 days. Statistical significance between groups is assessed using nonparametric one-way ANOVA. Mice are given the lactate salt of Onalespib using a repeated cycle of dosing of once per day for three days, no dose for three days, once per day for three days etc., for four dosing cycles at 60 mg/kg/dose (as free base equivalents) dissolved in 17.5% hydroxypropyl-β-cyclodextrin via the IP route. Control mice receive dose vehicle only via the same route. Tolerability is assessed by recording body weight, clinical observations and survival^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Woodhead AJ, et al. Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design. J Med Chem. 2010 Aug 26;53 [Content Brief]

[2]. Kang MH, et al. Initial testing (Stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2012 Jul 15;59(1):185-8. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.4419 mL	12.2094 mL	24.4188 mL	61.0471 mL
	5 mM	0.4884 mL	2.4419 mL	4.8838 mL	12.2094 mL
	10 mM	0.2442 mL	1.2209 mL	2.4419 mL	6.1047 mL
	15 mM	0.1628 mL	0.8140 mL	1.6279 mL	4.0698 mL
	20 mM	0.1221 mL	0.6105 mL	1.2209 mL	3.0524 mL
	25 mM	0.0977 mL	0.4884 mL	0.9768 mL	2.4419 mL
	30 mM	0.0814 mL	0.4070 mL	0.8140 mL	2.0349 mL
	40 mM	0.0610 mL	0.3052 mL	0.6105 mL	1.5262 mL
	50 mM	0.0488 mL	0.2442 mL	0.4884 mL	1.2209 mL
	60 mM	0.0407 mL	0.2035 mL	0.4070 mL	1.0175 mL
	80 mM	0.0305 mL	0.1526 mL	0.3052 mL	0.7631 mL
	100 mM	0.0244 mL	0.1221 mL	0.2442 mL	0.6105 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Onalespib

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

CNS-Penetrant Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Anti-COVID-19 Compound Library

Endoplasmic Reticulum Stress Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Anti-Lung Cancer Compound Library

Targeted Diversity Library

Anti-Prostate Cancer Compound Library

Metabolic Enzyme Compound Library

Extracellular Vesicles (EVs) Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Onalespib

All HSP Isoforms

Biological Activity

Chemical Information

Publications (11)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Onalespib

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

CNS-Penetrant Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Anti-COVID-19 Compound Library

Endoplasmic Reticulum Stress Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Anti-Lung Cancer Compound Library

Targeted Diversity Library

Anti-Prostate Cancer Compound Library

Metabolic Enzyme Compound Library

Extracellular Vesicles (EVs) Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Onalespib

All HSP Isoforms

Biological Activity

Chemical Information

Publications (11)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Onalespib Related Classifications

HY-14463 Related Classifications